Cancer name Kidney Renal Clear Cell Carcinoma
Cancer Type KIRC
Immunotherapy type Immune Checkpoint Therapy
Treatment nivolumab
Drugstatus Approved
Drugbank ID DB09035(DB06132)
Checkpoints PD-1
Signature Type Gene
Signature CD69
Official Symbol CD69
Mode of action TRAN_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental clinical trial phase 1b
Description Interestingly, the pharmacodynamic effects of nivolumab also include significant increases in the expression of genes linked to innate immunity and natural killer (NK) cell function (e.g., KLRB1/D1/G1, CD69, and NKG7), suggesting the testable hypothesis that nivolumab may boost T-cell–mediated antitumor immune activity through enhanced infiltration and/or stimulation of NK cells.
PMID 27169994
Title Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma